NeraCare Announces Publication of Abstract on Clinical Validation of a Prognostic 7-Biomarker Assay for Prediction of Relapse in Patients with Early-Stage Cutaneous Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Assay identified 98% of relapses and 100% of cutaneous melanoma-related deaths in stage IB/IIA patients Patients with stage IB/IIA melanoma identified as high-risk had a relapse rate comparable